Claudia Robles Hellin


Claudia Robles Hellin

Dr. Claudia Robles holds a Pharmacy degree (University of Barcelona-UB, 2004), a Master in Public Health (Pompeu Fabra University-UPF, 2010) and a Cum Laude PhD in Biomedicine (Pompeu Fabra University-UPF, 2014).

After 6 years working in oncology clinical trials for the pharmaceutical industry, in 2010 she joined the Cancer Epidemiology Research Program (PREC) in the Catalan Institute of Oncology (ICO), where she conducted her PhD studies on the role of polyomaviruses in lymphoproliferative disorders and bladder cancer, and participated in several epidemiological studies on other potential causes of lymphoproliferative disorders.

After completing her PhD she started working on cervical cancer prevention, exploring potential strategies to be used in developing countries such as HPV vaccination of adult women (HPV FASTER). To better understand the logistics and political complexities of the implementation of prevention strategies in resource-limited settings, she moved to the International Agency for Research on Cancer (IARC) for a two-years postdoctoral stay, where she explored quality indicators of cervical cancer screening in Colombia and the potential use of serum biomarkers for the prevention of gastric cancer.

In IARC she also assisted in the implementation of a breast cancer screening program in Belarus, and together with Dr. Raul Murillo she started a project to aid developing countries in collecting data on their own cancer screening activities, in order to (i) monitor, evaluate and adapt as necessary their programs and (ii) collect and homogenize worldwide data on cancer screening, which is the main aim of this project.

In 2017, she joined the UNIC-Information and Interventions team (UNIC-I) in PREC to continue working on HPV FASTER, by combining the expertise of ICO in HPV vaccination of adult women with that of IARC in HPV screening.

Since 2019, she coordinates the evaluation of performance and quality indicators of the opportunistic cervical cancer screening program with cytology in Catalonia using primary care health records. She is also assisting in the implementation of an organised HPV-based cervical cancer screening program, planned to be implemented by 2024 in Catalonia. She is also responsible for the dissemination and communication of a European Commission-funded project on risk-based cervical cancer screening, where she is coordinating the development of a course on HPV-based cervical cancer screening.

Since 2015, she collaborates with the online training platform e-oncología by developing the content and tutoring of courses related to cervical cancer prevention.

ResearcherID: G-5210-2015


Robles C, Bruni L, Acera A, et al. Determinants of HPV vaccine uptake by adult women attending cervical cancer screening in 9 European countries. Am J Prev Med. 2021 Apr;60(4):478-487. doi: 10.1016/j.amepre.2020.08.032

Murillo R, Robles C. Research Needs for Implementing Cancer Prevention and Early Detection in Developing Countries: From Scientists’ to Implementers’ Perspectives. Biomed Res Int. 2019 May 7;2019:1–12. doi: 10.1155/2019/9607803

Robles C, Wiesner C, Martinez S, et al. Impact of operational factors on HPV positivity rates in an HPV-based screening study in Colombia. Int J Gynaecol Obstet. 2018 Oct;143(1):44–51. doi: 10.1002/ijgo.12574

Robles C, Hernández M de la L, Almonte M. Alternative HPV vaccination schedules in Latin America. Salud Publica Mex. 2018 Dec 13;60(6):693–702. doi: 10.21149/9810

Bosch FX, Robles C. HPV-FASTER: Combined strategies of HPV vaccination and HPV screening towards a one visit for cervical cancer preventive campaigns. Salud Publica Mex. 2018 Dec 13;60(6):612–6. doi: 10.21149/10171

Salmerón J, Torres-Ibarra L, Bosch FX, Z, (…) Robles C, et al. HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico. Salud Publica Mex. 2016 Apr;58(2):211-9. doi: 10.21149/spm.v58i2.7790

Bosch FX, Robles C, Díaz M, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2016 Feb;13(2):119–32. doi: 10.1038/nrclinonc.2015.146